drugset / Trial / NCT01256905

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

NCT01256905

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced Parkinson's disease (PD) and Lewy body disease (LBD).

Timeline

Start
2011-01-01
Primary completion
2011-08-08
Completion
2011-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 150 mg